Similarly, more adverse RFS were observed in high MUC5AC group of ccRCC patients with TNM stage III + IV (HR, 9.504; 95% CI, 4.275 – 21.127; P < 0.001; Figure 2G). Here, MUC5AC is linked to nonpapillary renal cell carcinoma.